What an SBIR Award Is Actually Worth

A $700,000 award ceiling does not tell a company whether an application is worth preparing. The relevant comparison is between the development work an award could support and the cash, time, and alternatives committed to pursuing it.

For NIH applicants, that comparison has become less favorable: the aggregate SBIR/STTR success rate fell from 21.9% in FY2019 to 10.4% in FY2025. This does not make applying irrational. It makes the choice of project, mechanism, and submission cycle more consequential.

Award size: budget the milestone

NIH's general budget guidelines are $323,090 for Phase I and $2,153,927 for Phase II. Approved institute and topic limits can be higher. Selected limits in the current parent announcement illustrate why both phases belong in the assessment.

A higher Phase I limit does not necessarily imply more Phase II funding. Institute selection must still follow scientific fit, and requests above the general guidelines depend on the applicable waiver topics and announcement. These limits are not typical awards or promised budgets. NIH parent SBIR announcement.

Start with the experiment or development milestone and estimate its full cost, including personnel, facilities, indirect costs, and necessary external work. Then determine whether the permitted award can support it. An award that leaves a critical experiment unfunded may have less practical value than its face amount suggests.

Phase I should also produce evidence useful for the next decision, whether that is Phase II, private financing, a partnership, or stopping development. Later funding should remain a contingency rather than an assumed continuation.

Outsourcing changes the feasible work plan

Under NIH SBIR Phase I, third-party scientific and technical work normally cannot exceed 33% of total requested costs, including direct costs, indirect costs, and fee. On a $700,000 request, that is $231,000; on a $400,000 request, $132,000. Deviations require the applicable approval.

This is a limit on relevant outsourced research, not a reserve for consultants or a restriction on every purchase outside the company. Paying a CRO to perform essential experiments can still deliver substantial value to the company. The question is whether the proposed division of research complies with the mechanism.

STTR permits a different structure: at least 40% of the research by the company and at least 30% by one eligible nonprofit research institution. For a company whose essential capabilities remain at a university, this can change which plan is feasible. Do not transfer NIH's budget calculation unchanged to another agency. NIH SBIR requirements · NIH STTR requirements.

Competition: use the right comparison

Source: NIH RePORT Table 215, competing applications reviewed and awards made. These four rows are selected mechanisms, not the full program total.

STTR Phase I's observed rate was approximately 1.6 times SBIR Phase I's. That supports assessing STTR where a suitable institutional partnership exists. It does not establish a causal improvement from switching: applicant characteristics, science, and institute mix differ. Phase II rates concern a different development stage and should not be treated as probabilities available to a Phase I applicant.

Across the full NIH SBIR/STTR table, FY2025 had 47% more applications and 19% fewer awards than FY2023. The competitive environment has changed, but an aggregate rate is not a company-specific forecast. Multiplying the award ceiling by 7.8% does not produce a sufficient measure of application value: award funds support an approved project, and the company's costs and alternatives differ.

The cost is incurred before the outcome

Application costs include staff time, external assistance, institutional coordination, and work postponed while preparing the proposal. Obtain quotes for the actual scope and estimate internal effort separately; a consultant's fee is only one component.

A survey of 113 astronomers and 82 psychologists reported averages of 116 principal-investigator hours and 55 hours from other investigators combined per proposal. Those are historical academic estimates, not an NIH SBIR benchmark or a demonstrated minimum. The survey found no relationship between writing time and funding success, but that does not establish that proposal quality is unimportant or that submitting more applications is a superior strategy for a startup. von Hippel and von Hippel, 2015.

For planning purposes, the company needs to finance preparation before any award decision. Do not assume a future award will directly reimburse application-development costs; any recovery depends on the applicable cost principles and approved accounting treatment.

Timing: distinguish earliest start from cash availability

The NIH parent announcement places the September 2026 cycle's earliest start in April 2027, approximately seven months later. This is a published schedule, not an observed average or guaranteed payment date. The announcement accepts no late applications, subject to its stated deadline rules.

A company should assess whether it can maintain the necessary team and project through review and possible delay. If its runway is shorter, the application needs a credible bridge-financing or reduced-spending plan. The award cannot be the sole solution to a cash shortfall that occurs before it could start.

For other agencies, compare the specific solicitation's award size, review schedule, and research requirements. NSF adds a mandatory Project Pitch invitation before a Phase I or Fast Track proposal. Agency labels alone do not establish speed or suitability. NIH timetable · NSF solicitation.

Commercialization support and further attempts

NIH Technical and Business Assistance can provide up to $6,500 for Phase I and $50,000 for Phase II across the project period. Requests need justification and provider identification where applicable. NIH permits requests in the application and through post-award administrative supplements; supplemental funding is not guaranteed. Commercialization Readiness Pilot awards are excluded. TABA supports eligible activities, not unrestricted reimbursement of application costs. NIH TABA policy.

A further submission also has a cost. HHS limits covered Phase I, Fast Track, and Direct Phase II applications and proposals to nine per company per fiscal year. NIH separately limits specified PI applications to six across council rounds in a calendar year, with exceptions. The different counting periods mean neither limit invariably binds first. HHS company limit · NIH PI limit.

Plan for the possibility of revision without committing to it in advance. Reviewer feedback may support resubmission, a different opportunity, additional experiments, or stopping. Repeated applications should not be modeled as independent trials with an unchanged success probability.

Implications

An application is worth considering when the award can fund a consequential milestone, the research structure is eligible, and the company can absorb preparation costs and the wait for a decision. Scientific fit comes first; among suitable opportunities, budget, competition, timing, and obligations matter together.

The practical comparison is with the company's next-best use of the same resources. A larger award is not automatically more valuable, and a higher historical success rate does not compensate for a poor fit. Program selection and a credible work plan should precede drafting; the evidence does not rank their value against writing quality in monetary terms.

Related: The Strategic Value of SBIR Funding · The SBIR/STTR Funding Landscape · After the Summary Statement.